0001209191-23-059254.txt : 20231219 0001209191-23-059254.hdr.sgml : 20231219 20231219192246 ACCESSION NUMBER: 0001209191-23-059254 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231215 FILED AS OF DATE: 20231219 DATE AS OF CHANGE: 20231219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Virani Shafique CENTRAL INDEX KEY: 0001856081 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40323 FILM NUMBER: 231498968 MAIL ADDRESS: STREET 1: C/O RECURSION PHARMACEUTICALS STREET 2: 41 S. RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001601830 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464099738 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 BUSINESS PHONE: (385) 269-0203 MAIL ADDRESS: STREET 1: 41S RIO GRANDE STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84101 FORMER COMPANY: FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC DATE OF NAME CHANGE: 20140305 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-15 0 0001601830 RECURSION PHARMACEUTICALS, INC. RXRX 0001856081 Virani Shafique C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET SALT LAKE CITY UT 84101 0 1 0 0 Chief Business Officer 1 Class A Common Stock 2023-12-15 4 M 0 18000 2.22 A 154748 D Class A Common Stock 2023-12-15 4 S 0 18000 9.60 D 136748 D Stock Option (Right to Buy) 8.55 2033-02-01 Class A Common Stock 0 212507 D Stock Option (Right to Buy) 2.22 2023-12-15 4 M 0 18000 0.00 D 2030-03-03 Class A Common Stock 18000 379469 D Stock Option (Right to Buy) 11.40 2032-02-04 Class A Common Stock 0 80450 D Stock Option (Right to Buy) 11.40 2022-02-04 2032-02-04 Class A Common Stock 0 5436 D Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person on March 1, 2023. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. /s/ Jonathan Golightly, attorney-in-fact 2023-12-19